Mineralys Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Mineralys Therapeutics Inc 's ROA in the third quarter of 2026?
Mineralys Therapeutics Inc recorded a cumulative net loss of $-370 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -56.41%.

However, within the Healthcare sector 583 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3604, from total ROA ranking in the second quarter of 2026 at 4333.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	5.03 %	102.17 %	83.94 %	221.42 %	123.65 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-370	-350	-152	-155	-171
Return On Assets (TTM)	-56.41 %	-53.92 %	-26.98 %	-31.68 %	-45.8 %
MLYS's Total Ranking	# 3604	# 4333	# 4014	# 4273	# 4351
Total Assets (TTM) in million	630	679	653	662	600
Seq. Total Assets Change	-7.16 %	3.96 %	-1.35 %	10.31 %	78.7 %
Seq. Net Income Change	-	-	-	-	-

MLYS's 5 Years Annual ROA >> Back to MLYS Management Effectiveness >> Compare MLYS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 258
Sector	# 584
Overall	# 3957

Return On Assets Statistics
High	Average	Low
-25.52 %	-45.51 %	-65.71 %
(Dec 31 2023)		(Mar 31 2025)

Financial Statements
Mineralys Therapeutics Inc 's Assets	$ 630 million	MLYS's Balance sheet
Mineralys Therapeutics Inc 's Income	$ -57 million	Quarterly MLYS's Income Statement
MLYS's Income by Division		See MLYS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	221.42 %	-18 %	-	-	-
Total Assets in million	662	206	251	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-155	-178	-72	0	0
Annual Return On Assets	-23.37 %	-86.36 %	-28.63 %	-	-

MLYS's 5 Years Annual ROA >> Back to MLYS Management Effectiveness >> Compare MLYS ROA to its Competitors

More Return On Assets Ratios
MLYS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MLYS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MLYS's Competitors
Subscribers only: Roa for Mineralys Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for MLYS's Customers

You may also want to know
MLYS's Roi	MLYS's Inventory Turnover Ratio	MLYS's Growth Rates	MLYS's Dividend Comparisons
	MLYS's Profitability Ratios	MLYS's Asset Turnover Ratio	MLYS's Dividend Growth
MLYS's Roe	MLYS's Valuation Ratios	MLYS's Financial Strength Ratios	MLYS's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-05T05:19:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.